Page last updated: 2024-12-09

vu 0155041

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

VU 0155041: an mGluR4 agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID888023
CHEMBL ID578988
SCHEMBL ID359675
MeSH IDM0541034

Synonyms (27)

Synonym
(1r,2s)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexanecarboxylic acid
STK413206
vu-0155041
CHEMBL578988 ,
bdbm50301219
cis-2-(3,5-dichlorophenylcarbamoyl)cyclohexanecarboxylic acid
(1r,2s)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid
vu0155041
1093757-42-6
vu 0155041
gtpl3323
AKOS022168168
SCHEMBL359675
cis-2-[[(3,5-dichlorophenyl)amino]carbonyl]cyclohexanecarboxylic acid
(1r,2s)-vu0155041
HY-14417A
CS-6849
vu0155041, >=98% (hplc)
1263273-14-8
uv0155041
cis-2-[[(3,5-dichlorophenyl)amino]carbonyl]cyclohexane carboxylic acid
rel-(1r,2s)-2-((3,5-dichlorophenyl)carbamoyl)cyclohexane-1-carboxylic acid
( inverted exclamation marka)-cis-2-(3,5-dichlorophenylcarbamoy)cyclohexanecarboxylic acid
uv-0155041
Q27089175
(+/-)-cis-2-(3,5-dicholorphenylcarbamoyl)cyclohexanecarboxylic acid
MS-24648
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Metabotropic glutamate receptor 4Homo sapiens (human)EC50 (µMol)0.74500.00401.71939.8000AID447669; AID618715
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 4Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 4Homo sapiens (human)
neurotransmitter secretionMetabotropic glutamate receptor 4Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 4Homo sapiens (human)
regulation of neuron apoptotic processMetabotropic glutamate receptor 4Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 4Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneMetabotropic glutamate receptor 4Homo sapiens (human)
cytoplasmic vesicleMetabotropic glutamate receptor 4Homo sapiens (human)
presynapseMetabotropic glutamate receptor 4Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1346285Human mGlu4 receptor (Metabotropic glutamate receptors)2008Molecular pharmacology, Nov, Volume: 74, Issue:5
Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4.
AID618716Positive allosteric modulation of human mGlu4 receptor expressed in BHK cells assessed as potentiation of glutamate-induced response after 1 hr by FLIPR assay relative to glutamate2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators.
AID447669Allosteric modulator activity at human mGlu4 receptor expressed in CHO cells coexpressing Gqi5 assessed as effect on calcium flux2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4).
AID618715Positive allosteric modulation of human mGlu4 receptor expressed in BHK cells assessed as potentiation of glutamate-induced calcium mobilization after 1 hr by FLIPR assay2011Journal of medicinal chemistry, Jul-28, Volume: 54, Issue:14
Tricyclic thiazolopyrazole derivatives as metabotropic glutamate receptor 4 positive allosteric modulators.
AID447670Allosteric modulator activity at human mGlu4 receptor expressed in CHO cells coexpressing Gqi5 assessed as effect on calcium flux in relative to glutamate2009Bioorganic & medicinal chemistry letters, Sep-01, Volume: 19, Issue:17
Synthesis and SAR of a novel positive allosteric modulator (PAM) of the metabotropic glutamate receptor 4 (mGluR4).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (11.11)29.6817
2010's13 (72.22)24.3611
2020's3 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]